Last updated on February 2018

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)


Brief description of study

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional decline and prevents from disease progression in ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study, investigators aimed to assess the treatment effect of this newly approved drug in patients with ALS in a representative Iranian population.

Clinical Study Identifier: NCT03272802

Contact Investigators or Research Sites near you

Start Over

keivan basiri, Professor

EMG Department, Alzahra Hospital
Isfahan, Iran, Islamic Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.